Novo Nordisk

Novo Nordisk Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Novo Nordisk key operating metrics including Phase I Trials Products (Haemophilia), environmental, and social and governance score (ESG).

Phase I Trials Products (Haemophilia)

Q4, 2021

Trials Products Approved (Obesity)

Q3, 2022

Phase III Trials Products (Obesity)

100.0%

Q3, 2022

Operating Metrics

Metrics	Q1, 2020	Q2, 2020	Q3, 2020	Q4, 2020	Q1, 2021	Q2, 2021	Q3, 2021	Q4, 2021	Q2, 2022	Q3, 2022
Phase I Trials Products (Haemophilia)	2	2	2	1	1	1	1	1
Trials Products Approved (Obesity)	1	1	1	1	1	2	2	2	2	2
Phase III Trials Products (Obesity)	2	2	2	1			1	1	1	2
Phase II Trials Products (Obesity)	1	1	1	1	1	1	2	2	2	1
Phase I Trials Products (Obesity)	3	3	3	3	3	3	2	2	2	1
Trials Products Approved (Diabetes)	10	10	10	10	10	10	10	10	10	10
Phase III Trials Products (Diabetes)	2	2	4	6	2	2	2	3	3	3
Phase II Trials Products (Diabetes)	2	2	1			1	1	2	3	2
Phase I Trials Products (Diabetes)	4	4	5	7	7	7	7	4	4	6
Phase III Trials Products (Other Serious Chronic Diseases)	2	2			1	2	3	3	3	3
Phase II Trials Products (Other Serious Chronic Diseases)	2	2	3	3	2	3	3	4	5	4
Phase I Trials Products (Other Serious Chronic Diseases)	3	3	4	3	3	3	2	3	1	1
Trials Products Approved (Growth Disorders)	2	2			2	2	2	2	2	2
Trials Products Submitted (Growth Disorders)	1	1	1						1	2
Phase III Trials Products (Growth Disorders)	1	1	1	1	1	1	1	2	1
Phase II Trials Products (Growth Disorders)	1	1	1	1	1	1	1
Trials Products Approved (Haemophilia)	5	5	6	6	5	5	5	5	5	5
Phase III Trials Products (Haemophilia)	1	1	1	1	1	1	1	3	3	1
Phase II Trials Products (Haemophilia)				1	1	1	1		1	2
Trials Products Submitted (Obesity)				1	1	1	1
Trials Products Submitted (Diabetes)				1	1	1	1	1
Trials Products Submitted (Haemophilia)										2

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub